Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Total Liabilities: 2020-2024

Historic Total Liabilities for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $15.4 million.

  • Mereo BioPharma Group's Total Liabilities fell 56.79% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 56.79%. This contributed to the annual value of $15.4 million for FY2024, which is 3.39% down from last year.
  • Latest data reveals that Mereo BioPharma Group reported Total Liabilities of $15.4 million as of FY2024, which was down 3.39% from $16.0 million recorded in FY2023.
  • Mereo BioPharma Group's 5-year Total Liabilities high stood at $100.1 million for FY2020, and its period low was $15.4 million during FY2024.
  • Its 3-year average for Total Liabilities is $19.1 million, with a median of $16.0 million in 2023.
  • Data for Mereo BioPharma Group's Total Liabilities shows a maximum YoY slumped of 49.77% (in 2022) over the last 5 years.
  • Mereo BioPharma Group's Total Liabilities (Yearly) stood at $100.1 million in 2020, then slumped by 48.25% to $51.8 million in 2021, then slumped by 49.77% to $26.0 million in 2022, then crashed by 38.63% to $16.0 million in 2023, then declined by 3.39% to $15.4 million in 2024.